Pluristem Therapeutics, Inc. (NASDAQ:PSTI) is set to issue its Q4 quarterly earnings data after the market closes on Monday, September 11th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Shares of Pluristem Therapeutics, Inc. (NASDAQ PSTI) opened at 1.17 on Friday. The company’s market capitalization is $112.71 million. Pluristem Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $1.70. The firm’s 50-day moving average is $1.17 and its 200-day moving average is $1.27.

A number of equities analysts have commented on PSTI shares. HC Wainwright reiterated a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a report on Monday, May 15th. Maxim Group reiterated a “hold” rating on shares of Pluristem Therapeutics in a report on Monday, May 22nd. Finally, ValuEngine downgraded shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $3.19.

ILLEGAL ACTIVITY WARNING: “Pluristem Therapeutics, Inc. (PSTI) Scheduled to Post Quarterly Earnings on Monday” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Stock Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related stocks with our FREE daily email newsletter.